What Is CJC-1295/Ipamorelin?
A combination protocol using CJC-1295 without DAC (also known as Mod GRF 1-29) and Ipamorelin through complementary receptor mechanisms. CJC-1295 without DAC has a short half-life of 30 minutes to 2 hours, enabling pulsatile GH release that mimics natural physiology. Ipamorelin provides selective GH release without affecting cortisol, ACTH, or prolactin. Note: This protocol specifically uses the no-DAC version for pulsatile release patterns.
Quick Reference
Member reference tables summarize the compound's research parameters.
Key Benefits
- Synergistic dual-pathway stimulation — CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin receptors, amplifying GH release 2–3x over either peptide alone
- In published studies, ipamorelin stimulated growth-hormone release without notable increases in cortisol, ACTH or prolactin.
- Pulsatile release pattern mimics natural physiology, reducing receptor desensitization versus continuous GH elevation
Mechanism of Action
CJC-1295 (no DAC / Mod GRF 1-29) binds GHRH receptors on pituitary somatotrophs, driving cAMP production and GH synthesis. Its short half-life (30 min–2 hrs) due to DPP-IV cleavage produces a sharp pulse rather than sustained elevation. Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) via a distinct PKC/IP3 pathway, amplifying GH release without affecting cortisol, ACTH, or prolactin. The two peptides act on different receptors (GHRH receptors and ghrelin receptors), and studies of each describe a short, pulse-like growth-hormone response.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Reported Research Time Points
This member section summarizes reported research time points.
Research Citations
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman, S.L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J.P., & Frohman, L.A., 2006, Journal of Clinical Endocrinology & Metabolism - Ipamorelin, the first selective growth hormone secretagogue
Raun, K., Hansen, B.S., Johansen, N.L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P.H., 1998, European Journal of Endocrinology - Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
Ionescu, M. & Frohman, L.A., 2006, Journal of Clinical Endocrinology & Metabolism - Ghrelin and growth hormone secretagogues potentiate GHRH-induced cAMP production
Cunha, S.R., & Mayo, K.E., 2002, Endocrinology - Molecular recognition of an acyl-peptide hormone and activation of ghrelin receptor
Wang, X., Qin, C., Zhao, L.H., et al., 2021, Nature Communications - Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
Gobburu, J.V.S., Agersø, H., Jusko, W.J., & Ynddal, L., 1999, Pharmaceutical Research - Desensitization and endocytosis mechanisms of ghrelin-activated growth hormone secretagogue receptor 1a
Camiña, J.P., Carreira, M.C., El Messari, S., Llorens-Cortes, C., Smith, R.G., & Bhattacharya, S., 2004, Endocrinology - The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration
Dominikowski A, Rękoś Z, Olejarz M, 2026, Front Endocrinol (Lausanne)